Analyzing Regeneron Pharmaceuticals Stock Performance

By Tamara Parker • Wednesday, April 30 09:57 • Permanent Link

Regeneron Pharmaceuticals logged a 0.4% change during today's morning session, and is now trading at a price of $571.03 per share. The S&P 500 index moved -2.0%. REGN's trading volume is 167,455 compared to the stock's average volume of 1,044,709.

Regeneron Pharmaceuticals trades -30.18% away from its average analyst target price of $817.92 per share. The 24 analysts following the stock have set target prices ranging from $547.0 to $979.0, and on average have given Regeneron Pharmaceuticals a rating of buy.

Anyone interested in buying REGN should be aware of the facts below:

Regeneron Pharmaceuticals's current price is 21.7% above its Graham number of $469.04, which implies that at its current valuation it does not offer a margin of safety
Regeneron Pharmaceuticals has moved -37.0% over the last year, and the S&P 500 logged a change of 10.8%
Based on its trailing earnings per share of 39.31, Regeneron Pharmaceuticals has a trailing 12 month Price to Earnings (P/E) ratio of 14.5 while the S&P 500 average is 29.3
REGN has a forward P/E ratio of 12.6 based on its forward 12 month price to earnings (EPS) of $45.31 per share
Its Price to Book (P/B) ratio is 2.06 compared to its sector average of 3.19
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
Based in Tarrytown, the company has 15,158 full time employees and a market cap of $61.65 Billion. Regeneron Pharmaceuticals currently returns an annual dividend yield of 0.2%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.